Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-39,935
Closed -$35.1K 781
2025
Q4
$35.1K Sell
39,935
-7,260
-15% -$7.76K ﹤0.01% 759
2025
Q3
$64.2K Buy
+47,195
New +$71.4K ﹤0.01% 757
2025
Q2
Sell
-15,114
Closed -$39.9K 804
2025
Q1
$39.9K Hold
15,114
﹤0.01% 793
2024
Q4
$64.1K Buy
+15,114
New +$58.2K ﹤0.01% 818
2023
Q3
Sell
-249,000
Closed -$2.33M 921
2023
Q2
$2.33M Hold
249,000
0.02% 643
2023
Q1
$2.15M Buy
+249,000
New +$2.2M 0.02% 644

Other funds holding DCGO

Royce & Associates's DCGO Position: Q1 2026 in Review

Royce & Associates sold out of DocGo (DCGO) in Q1 2026, closing a stake of 39,935 shares — an estimated $35.1K sold.

Royce & Associates first reported a position in DCGO in Q1 2023 and held it in 6 quarters. The position peaked at $2.33M in Q2 2023. 123 funds tracked by Wall St. Rank hold DCGO as of Q1 2026.

  • Royce & Associates reported no remaining DocGo position as of Q1 2026 after selling out during the quarter.
  • Royce & Associates sold 39,935 DocGo shares in Q1 2026, an estimated $35.1K.
  • Royce & Associates first reported a position in DocGo in Q1 2023 and held it in 6 quarters.
  • Royce & Associates's DocGo position peaked at $2.33M in Q2 2023.
  • 123 funds tracked by Wall St. Rank held DocGo as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.